Abstract:

The clinical manifestations, pathological characteristics, neoadjuvant treatment plan, heterogeneity changes in tumor genes, Miller-Payne (MP) classification, and surgery and other treatment plans of a patient with refractory locally advanced triple-negative breast cancer admitted to General Surgery, Tianjin Medical University General Hospital were analyzed. A specific subgroup of refractory locally advanced triple-negative breast cancer patients experiences molecular subtype conversion and molecular gene heterogeneity changes after neoadjuvant chemotherapy, which enhances the sensitivity of triple-negative breast cancer patients to conventional resistant chemotherapy regimens and improves their final comprehensive treatment decision-making. This kind of disease is relatively rare in actual clinical treatment, and it is easy for certain groups of people to be misdiagnosed and delayed in treatment. It helps to gradually form a consensus on treatment to summarize this kind of cases.

Key words:

Neoadjuvant chemotherapy, Tumor gene heterogeneity, Triple-negative breast cancer, Gene

摘要：

对天津医科大学总医院普通外科收治的1例难治性局部晚期三阴性乳腺癌患者的临床表现、病理特征、新辅助治疗方案、肿瘤基因异质性改变、Miller-Payne（MP）分级、手术等治疗方案进行分析研究。难治性局部晚期三阴性乳腺癌患者的特定亚群在新辅助化疗后出现分子亚型转换及分子基因异质性变化，增强了患者对常规易耐药化疗方案的敏感性，改善其最终的综合治疗决策。该种病患在实际临床治疗中较为罕见，易对特定人群出现误诊迟治。现对该种病例进行归纳总结，有助于逐步形成治疗共识。

关键词:

新辅助化疗, 肿瘤异质性, 三阴性乳腺癌, 基因